ReviewFrontiers in immunology2019
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non-small cell lung cancer.Aging medicine (Milton (N.S.W)) · 2024Review
- Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases.Cancers · 2023Review
- The use of RNA-based treatments in the field of cancer immunotherapy.Molecular cancer · 2023Review
- Morphine suppresses the immune function of lung cancer by up-regulating MAEL expression.BMC pharmacology & toxicology · 2022Article
- Lung Cancer Stem Cells and Their Clinical Implications.Cold Spring Harbor perspectives in medicine · 2022Review
- Article
- Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.Exploration of targeted anti-tumor therapy · 2022Review
- mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions.Frontiers in immunology · 2022Article
- CD8Frontiers in immunology · 2022Article
- Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy.Cancers · 2021Review
- Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions.Oncology letters · 2021Review
- Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer.Oncology letters · 2021Article
- Molecular profiles of small cell lung cancer subtypes: therapeutic implications.Molecular therapy oncolytics · 2021Review
- Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.Nano-micro letters · 2021Review
- Clinical and immunological effects of mRNA vaccines in malignant diseases.Molecular cancer · 2021Review
- Recent progress on MHC-I epitope prediction in tumor immunotherapy.American journal of cancer research · 2021Review
- Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.Advances in experimental medicine and biology · 2021Article
- Polymorphisms of Antigen-Presenting Machinery Genes in Non-Small Cell Lung Cancer: Different Impact on Disease Risk and Clinical Parameters in Smokers and Never-Smokers.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in lung cancer treatment are emerging from new immunotherapies that target T-cell inhibitory receptors, such as programmed cell death-1 (PD-1). However, responses to anti-PD-1 antibodies as single agents are observed in fewer than 20% of non-small-cell lung cancer (NSCLC) patients, and immune mechanisms involved in the response to these therapeutic interventions remain poorly elucidated. Accumulating evidence indicates that effective anti-tumor immunity is associated with the presence of T cells directed toward cancer neoepitopes, a class of major histocompatibility complex (MHC)-bound peptides that arise from tumor-specific mutations. Nevertheless, tumors frequently use multiple pathways to escape T-cell recognition and destruction. In this regard, primary and acquired resistance to immune checkpoint blockade (ICB) therapy was associated with alterations in genes relevant to antigen presentation by MHC-class I/beta-2-microglobulin (MHC-I/β2m) complexes to CD8 T lymphocytes. Among additional known mechanisms involved in tumor resistance to CD8 T-cell immunity, alterations in transporter associated with antigen processing (TAP) play a major role by inducing a sharp decrease in surface expression of MHC-I/β2m-peptide complexes, enabling malignant cells to evade cytotoxic T lymphocyte (CTL)-mediated killing. Therefore, development of novel immunotherapies based on tumor neoantigens, that are selectively presented by cancer cells carrying defects in antigen processing and presentation, and that are capable of inducing destruction of such transformed cells, is a major challenge in translational research for application in treatment of lung cancer. In this context, we previously identified a non-mutant tumor neoepitope, ppCT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.